Vycor Launches New Extension Arm for Its Patented ViewSite(TM) Brain Access System (VBAS)
15 April 2013 - 10:30PM
Marketwired
Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO) announced today that it
has finalized the production and the U.S. commercial launch of an
extension arm for its existing ViewSite™ Brain Access System
("VBAS") product range. It is currently anticipated that the
extension arm will be available in Europe by the end of April.
VBAS is a suite of clear cylindrical disposable devices which
provide neurosurgeons a stable, minimally invasive working channel
to access targeted sites within the brain, such as tumors. The
"blade retractor" has been the standard of care device for brain
access and retraction for more than 50 years. VBAS is now approved
in over 100 hospitals in the U.S. and the number continues to grow.
To date, more than 4,000 surgeries have been performed utilizing
VBAS.
As part of Vycor's strategy to drive growth in the use of its
existing VBAS product range, the Company is developing ancillary
products that would facilitate its use. To this end, the Company
has launched in the U.S. the new extension arm (a non-disposable
accessory to the existing VBAS product) which connects to the
protruding tab of the VBAS working channel. This attachment arm
gives the surgeon more space to operate as well as the ability to
have the VBAS flush with the corticotomy. It is compatible with
most arms that come off the halo and will provide additional
functionality with most image-guided systems by providing a
connection point for the tracker of the IGS. This device is a
re-usable ancillary product that will be sold separately to
hospitals.
"We are very excited by the availability of the new VBAS
Extension Arm which we believe will help drive our VBAS sales and
help it become the de-facto new Standard of Care when it comes to
brain access and retraction. Prior to the introduction of any new
complementary VBAS devices, our existing VBAS product range already
address approximately 200,000 annual applicable procedures in the
U.S. alone, and we anticipate this new extension arm will further
help drive the product's adoption," stated David Cantor, Vycor's
President.
About Vycor Medical, Inc. With corporate
headquarters in Boca Raton, FL, Vycor Medical, Inc. ("Vycor") is a
publicly traded company (OTCBB: VYCO) dedicated to providing the
medical community with innovative and superior surgical and
therapeutic solutions and has a growing portfolio of FDA-approved
medical solutions that are changing and improving lives every day.
The Company operates two business units: Vycor Medical and
NovaVision, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating revenue.
The Company has a strong patent portfolio with 32 granted patents
and a further 23 patents pending.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient discharge.
VBAS is designed to optimize neurosurgical site access, reduce
patient risk, accelerate recovery and add tangible value to the
professional medical community. Vycor Medical is ISO 13485:2003
compliant, has FDA 510(K) clearance for VBAS for brain and spine
surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision develops and provides science-driven neurostimulation
therapy and other medical technologies that help improve and
partially restore sight in patients with neurological vision
impairments. The company's proprietary Visual Restoration
Therapy® (VRT) platform is clinically
supported to improve lost vision resulting from stroke, traumatic
brain injury ("TBI"), or other acquired brain injuries. VRT is the
only FDA 510K cleared medical device in the U.S. aimed at the
restoration of vision for neurologically induced vision loss and
can be prescribed by any ophthalmologist, optometrist, neurologist
or physiatrist. VRT also has CE Marking for the EU. NovaVision also
provides Neuro-Eye Therapy (NeET) in the EU, aimed at increasing
visual sensitivity deep within the field defect. NovaVision also
provides a fully portable and ADA-compliant Head Mounted Perimeter
(HMP™) which aids in the detection and measurement of visual field
deficits. For an overview of NovaVision see
http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute
forward-looking statements or statements which may be deemed or
construed to be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. The words
"forecast", "anticipate", "estimate", "project", "intend",
"expect", "should", "believe", and similar expressions are intended
to identify forward-looking statements. These forward-looking
statements involve, and are subject to known and unknown risks,
uncertainties and other factors which could cause Vycor Medical's
actual results, performance (financial or operating) or
achievements to differ from the future results, performance
(financial or operating) or achievements expressed or implied by
such forward-looking statements. The risks, uncertainties and other
factors are more fully discussed in Vycor Medical's filings with
the U.S. Securities and Exchange Commission. All forward-looking
statements attributable to Vycor Medical herein are expressly
qualified in their entirety by the above-mentioned cautionary
statement. Vycor Medical disclaims any obligation to update
forward-looking statements contained in this estimate, except as
may be required by law.
Vycor Medical, Inc Investor Contacts: The Del Mar
Consulting Group, Inc. Robert B. Prag President 858-794-9500 Email
Contact or Alex Partners, LLC Scott Wilfong President 425- 242-0891
Email Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024